[RI Therapy for Hematopoietic Tumors, Targeted α-Particle Therapy, and Future Prospects for Nuclear Medicine Therapies].

Abstract

Nuclear medicine treatment is a treatment in which RI is administered to patients, and hematopoietic tumors were treated with 90Y-conjugated anti-CD20 antibodies for low-grade B-cell lymphoma from 2008 to 2021. Targeted α-particle therapy has attracted attention because they have a remarkable therapeutic effect and is effective in cases refractory to β-particle therapy. In Japan, astatine-211(211At)-labeled drugs are being developed due to the restriction of the production and supply of actinium-225(225Ac). Because hematopoietic tumors are sensitive to radiation and suitable for nuclear medicine therapy, the authors have been developing therapy with α radionuclides that target CD82, which is highly expressed in hematopoietic tumor stem cells. Overseas, the development of nuclear medicine treatment is progressing, and new drugs are being applied clinically one after another. In Japan, corporate clinical trials have been conducted and approved earlier than before. As a result, there will be a shortage of radiotherapy rooms that provide treatment and specialized medical personnel engaged in the treatment. In this article, we look at the future of conventional nuclear medicine therapies for hematopoietic tumors, the development of targeted α-particle therapy, and the problems as mentioned above.